Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab, Nivolumab and SRT in Metastatic ccRCC
NCT03149159Phase 2Withdrawn
- Sponsor
- Medical University of South Carolina
- Start
- Apr 2018
- Primary completion
- Apr 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ipilimumab in clear cell renal cell carcinoma (ccRCC), sponsored by Medical University of South Carolina. Planned start Apr 2018; status: withdrawn.
02
Drugs
ipilimumab
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT03149159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03149159.